Dorothy Elizabeth Kelly-Gemmell
CIK: 0002144542
Transaction Breakdown
Open Market Buys (P)0 (0.0%)
High conviction signal
Open Market Sales (S)0 (0.0%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)1 (100.0%)
Compensation grants
Other (G, F, J, C, D, …)0 (0.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
VKTX
Viking Therapeutics, Inc.
Director
Discretionary Trading P&L
Holdings
About Kelly-Gemmell Dorothy Elizabeth
Kelly-Gemmell Dorothy Elizabeth (SEC CIK 0002144542) files insider reports with the SEC as Director of Viking Therapeutics, Inc. (VKTX).
Signal8 holds 2 ownership filings by Kelly-Gemmell Dorothy Elizabeth (1 Form 3, 1 Form 4), filed on Aug 7, 2026. Those filings report 1 transaction, the latest on Aug 1, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Kelly-Gemmell Dorothy Elizabeth's filings is in SAN DIEGO, CA.
Recent filings by Kelly-Gemmell Dorothy Elizabeth
- Aug 1, 2026: Grant or award of VKTX shares (Form 4, code A).
Other insiders filing for Viking Therapeutics, Inc. (VKTX)
- Lian Brian, President & CEO
- ZANTE GREG, Chief Financial Officer
- Mancini Marianna, Chief Operating Officer
- Chen Hubert C, Chief Medical Officer
- Aubuchon Neil William, Chief Commercial Officer
- SINGLETON J MATTHEW, Director